These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23561044)

  • 21. The importance of the vaginal delivery route for antiretrovirals in HIV prevention.
    Ferguson LM; Rohan LC
    Ther Deliv; 2011 Dec; 2(12):1535-50. PubMed ID: 22468220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
    Friend DR; Kiser PF
    Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical microbicides for prevention of sexually transmitted infections.
    Obiero J; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The future of HIV microbicides: challenges and opportunities.
    Garg AB; Nuttall J; Romano J
    Antivir Chem Chemother; 2009; 19(4):143-50. PubMed ID: 19374141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial.
    Friedland BA; Stoner M; Chau MM; Plagianos MG; Govender S; Morar N; Altini L; Skoler-Karpoff S; Ahmed K; Ramjee G; Monedi C; Maguire R; Lähteenmäki P
    AIDS Behav; 2016 Nov; 20(11):2565-2577. PubMed ID: 26204987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microbicides development programme: engaging the community in the standard of care debate in a vaginal microbicide trial in Mwanza, Tanzania.
    Vallely A; Shagi C; Lees S; Shapiro K; Masanja J; Nikolau L; Kazimoto J; Soteli S; Moffat C; Changalucha J; McCormack S; Hayes RJ
    BMC Med Ethics; 2009 Oct; 10():17. PubMed ID: 19814830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twice-daily application of HIV microbicides alter the vaginal microbiota.
    Ravel J; Gajer P; Fu L; Mauck CK; Koenig SS; Sakamoto J; Motsinger-Reif AA; Doncel GF; Zeichner SL
    mBio; 2012 Dec; 3(6):. PubMed ID: 23249810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Educating men about vaginal microbicides: considerations from Kenya.
    Gitome SW; Kwena ZA; Harper CC; Cohen CR; Bukusi EA
    Cult Health Sex; 2020 Jun; 22(6):660-674. PubMed ID: 31241426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
    Succop SM; MacQueen KM; van Loggerenberg F; Majola N; Karim QA; Karim SS
    AIDS Care; 2014; 26(12):1521-5. PubMed ID: 25285564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Women and ARV-based HIV prevention - challenges and opportunities.
    Geary CW; Bukusi EA
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19356. PubMed ID: 25224621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravaginal and menstrual practices among women working in food and recreational facilities in Mwanza, Tanzania: implications for microbicide trials.
    Allen CF; Desmond N; Chiduo B; Medard L; Lees SS; Vallely A; Francis SC; Ross DA; Hayes RJ
    AIDS Behav; 2010 Oct; 14(5):1169-81. PubMed ID: 20665101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding".
    Montgomery ET; van der Straten A; Stadler J; Hartmann M; Magazi B; Mathebula F; Laborde N; Soto-Torres L
    AIDS Behav; 2015 May; 19(5):784-93. PubMed ID: 25416076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Women's interest in vaginal microbicides.
    Darroch JE; Frost JJ
    Fam Plann Perspect; 1999; 31(1):16-23. PubMed ID: 10029928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sexuality, HIV risk and potential acceptability of involving adolescent girls in microbicide research in Kisumu, Kenya.
    Montandon M; Sahin-Hodoglugil NN; Bukusi E; Agot K; Boland B; Cohen CR
    Sex Health; 2008 Dec; 5(4):339-46. PubMed ID: 19061553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India.
    Greene E; Batona G; Hallad J; Johnson S; Neema S; Tolley EE
    Cult Health Sex; 2010 Oct; 12(7):739-54. PubMed ID: 20397080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The implications of post-coital intravaginal cleansing for the introduction of vaginal microbicides in South Africa.
    Gafos M; Pool R; Mzimela MA; Ndlovu HB; McCormack S; Elford J;
    AIDS Behav; 2014 Feb; 18(2):297-310. PubMed ID: 24337726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of partnership change on microbicide gel adherence in a clinical trial (HPTN 035).
    Gorbach PM; Kelly CW; Borgerding JA; Ramjee G; Tembo T; Kumwenda N; Musara P; Roberts S; Maslankowski L
    AIDS Behav; 2014 May; 18(5):855-61. PubMed ID: 24158488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microbicides for HIV prevention: reality or hope?
    McGowan I
    Curr Opin Infect Dis; 2010 Feb; 23(1):26-31. PubMed ID: 19935418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microbicides for the prevention of sexually transmitted HIV infection.
    Karim QA; Baxter C
    Expert Rev Anti Infect Ther; 2013 Jan; 11(1):13-23. PubMed ID: 23428099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.
    Mngadi KT; Maarschalk S; Grobler AC; Mansoor LE; Frohlich JA; Madlala B; Ngcobo N; Abdool Karim SS; Abdool Karim Q
    AIDS Behav; 2014 May; 18(5):849-54. PubMed ID: 24633715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.